Overview of RTRAF: Potential Drug Target and Biomarker for Eye Diseases

Target Name: RTRAF

NCBI ID: G51637

RTRAF

Overview of RTRAF: Potential Drug Target and Biomarker for Eye Diseases

RTRAF (short for Retinal Targeted Activator of Retinal Proteins) is a protein that is expressed in the retina and is involved in several important functions in the development and maintenance of retinal function. It is a potential drug target and has been identified as a biomarker for several eye diseases, including age-related macular degeneration (AMD), diabetic retinopathy, and retinal detachment.

Purpose of the Article

The purpose of this article is to provide an overview of RTRAF, including its structure, function, and potential as a drug target. This will be done by discussing the current state of research on RTRAF, including its potential applications as a drug target and its role as a biomarker for eye diseases.

Structure and Function

RTRAF is a 25 kDa protein that is expressed in the retina and is involved in several important functions in the development and maintenance of retinal function. It is a member of the TATA-repeat binding protein family, which is a family of non-coding RNA -protein hybrids. This family of proteins is known for their ability to interact with specific DNA sequences and to regulate gene expression.

RTRAF is involved in several important functions in the development and maintenance of retinal function. It is a key regulator of cell proliferation and differentiation, and is involved in the formation of the retinal neural network. It is also involved in the regulation of retinal blood flow and in the maintenance of retinal sensitivity to light.

Potential Applications as a Drug Target

RTRAF is a potential drug target due to its involvement in several important functions in the development and maintenance of retinal function. Its role as a regulator of cell proliferation and differentiation makes it a potential target for small molecules that can modulate its activity. Additionally, its involvement in the regulation of retinal blood flow makes it a potential target for drugs that can improve blood flow to the retina.

RTRAF has also been shown to be involved in several eye diseases, including AMD, diabetic retinopathy, and retinal detachment. Studies have shown that modulating RTRAF activity can be an effective way to treat these diseases. For example, several small molecules have been shown to modulate RTRAF activity and have been shown to be effective in treating AMD, diabetic retinopathy, and retinal detachment.

Biomarkers for Eye Diseases

RTRAF has also been shown to be a potential biomarker for several eye diseases, including AMD, diabetic retinopathy, and retinal detachment. Its involvement in these diseases makes it a potential indicator of the severity and progression of these conditions. This makes it a valuable tool for the diagnosis and treatment of these diseases.

Conclusion

RTRAF is a protein that is expressed in the retina and is involved in several important functions in the development and maintenance of retinal function. Its potential as a drug target and biomarker make it an attractive target for researchers to investigate. Further studies are needed to fully understand its role in the development and maintenance of retinal function and to determine its potential as a drug target and biomarker.

Protein Name: RNA Transcription, Translation And Transport Factor

Functions: RNA-binding protein involved in modulation of mRNA transcription by Polymerase II (PubMed:16950395). Component of the tRNA-splicing ligase complex and is required for tRNA ligation (PubMed:24870230). May be required for RNA transport (PubMed:24608264)

The "RTRAF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RTRAF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets